USPTO reveals 2013 fee changes

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

USPTO reveals 2013 fee changes

The USPTO has published new fees, most of which come into force on March 19

The changes will see reductions to the basic filing fee for utility patents (down to $280 from $380 for large entities) and design patents (reduced from $250 to $180).

Issue fees will be reduced and the $300 publication fee will be abolished in January 2014.

But maintenance fees are being increased, by between 26% and 56%.

There are also changes to claim fees, RCE fees, appeals, ex parte re-examination and inter partes reviews.

The fee changes result from the America Invents Act, which requires the USPTO to recover sufficient fees to cover its costs.

The agency proposed fee rules in September last year, and has reduced some fees in response to feedback received since then.

There are discounts for small and micro entities of up to 75% on many fees.

The full list of new fees is available on the USPTO website. Dennis Crouch on Patently O has summarised the major changes.

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article